Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Facioscapulohumeral muscular dystrophy (FSHD) is a heterogeneous disorder characterized by progressive facial and scapular muscle weakness. Recent evidence indicates that LRIF1 plays a critical role in maintaining chromatin organization, and disruption of its function contributes to the pathogenesis of FSHD. Multiple studies have now implicated LRIF1 through both genetic and functional analyses, highlighting its clinical importance for diagnostic decision‑making and patient stratification.
A homozygous nonsense variant, c.869_872dup (p.Trp291Ter) (PMID:32467133), was identified in a patient exhibiting a clinical phenotype consistent with FSHD. This variant causes a loss‑of‑function due to the absence of the long isoform of the LRIF1 protein. Additional multi‑patient studies have underscored the involvement of LRIF1 as a genetic modifier in FSHD, where screening by whole exome sequencing revealed LRIF1 variants among other known chromatin regulators in affected individuals (PMID:37674478).
Although detailed segregation data remained limited, family‐based analyses were performed in multi‑patient cohorts to assess the inheritance and phenotypic consistency of LRIF1 variants. These analyses, together with the identification of a homozygous variant, further support an autosomal recessive mode of disease transmission in this context. The genetic evidence, therefore, reinforces the significance of LRIF1 in FSHD even in the absence of extensive familial segregation counts.
Functional studies lend further credence to the pathogenic role of LRIF1 in FSHD. Experiments in both skeletal muscle cells and mouse embryonic stem cells have demonstrated that loss‑of‑function of LRIF1 leads to D4Z4 chromatin relaxation and subsequent de‑repression of DUX4, an aberrant event known to underlie FSHD molecular pathology (PMID:39605603). These findings highlight that LRIF1 is essential for chromatin compaction and gene silencing, and that its disruption produces experimental phenotypes consonant with the human disease.
The combined genetic and functional evidence supports a strong association between LRIF1 and facioscapulohumeral muscular dystrophy. The identification of a clearly deleterious homozygous LRIF1 variant, corroborated by multi‑patient genetic studies and functional assays, establishes LRIF1 as a bona fide disease gene for FSHD. This integrated analysis enhances our understanding of the underlying molecular mechanisms and informs both molecular diagnostics and potential therapeutic approaches.
Key take‑home: Robust genetic and functional support for LRIF1 in FSHD underscores its clinical utility as a diagnostic marker and a target for precision medicine in muscular dystrophy.
Gene–Disease AssociationStrongA homozygous LRIF1 variant was identified in a patient with FSHD features, demonstrating key molecular hallmarks such as D4Z4 chromatin relaxation and DUX4 misexpression ([PMID:32467133], [PMID:37674478]). Genetic EvidenceStrongThe detection of the c.869_872dup (p.Trp291Ter) variant in LRIF1 along with supportive findings from whole exome sequencing studies establishes a robust genetic link to FSHD ([PMID:32467133], [PMID:37674478]). Functional EvidenceModerateFunctional assays in muscle cells and mouse embryonic stem cells show that loss of LRIF1 leads to de‑repression of DUX4 via altered chromatin compaction, aligning with FSHD pathomechanisms ([PMID:39605603]). |